Ivantis To Pay $60M To End Patent Fight Over Glaucoma Tech

By Tiffany Hu (September 15, 2021, 4:50 PM EDT) -- Glaukos Corp. and Ivantis Inc. have inked a $60 million deal to end their patent dispute over therapies for treating glaucoma, the companies announced Wednesday.

The companies said that under the agreement, Ivantis will pay $60 million, with half being paid by Dec. 31, and the other half to be paid by Dec. 3, 2022. Ivantis will also pay a 10% royalty until April 26, 2025, on its Hydrus Microstent devices sold or imported into the U.S., they said.

As part of the deal, Glaukos said the companies will ask a California federal judge to pause a patent infringement lawsuit Glaukos...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!